CN103585140A

CN103585140A - Application of EPA (Eicosapetaenoic Acid) in preparing medicament for treating potassium bromate induced oxidative stress renal injury

Info

Publication number: CN103585140A
Application number: CN201310591758.2A
Authority: CN
Inventors: 王季凤; 李彦敏
Original assignee: SUZHOU MICROWANTS BIOLOGICAL TECHNOLOGY Co Ltd
Current assignee: SUZHOU MICROWANTS BIOLOGICAL TECHNOLOGY Co Ltd
Priority date: 2013-11-22
Filing date: 2013-11-22
Publication date: 2014-02-19

Abstract

The invention discloses an application of EPA (Eicosapetaenoic Acid) in preparing a medicament for treating potassium bromate induced oxidative stress renal injury, and belongs to the field of medical product study and development. According to the application, EPA is used as a medicament for treating potassium bromate induced organism oxidative stress renal injury, and a novel application of EPA in the pharmaceutical field is developed. Research result shows that EPA is capable of remarkably reducing serum creatinine levels of potassium bromate induced oxidative stress renal injury mice, and can be used for preparing a medicament for protecting potassium bromate induced organism oxidative stress renal injury.

Description

The application of EPA in preparing Potassium bromate. induced oxidation irritability injury of kidney medicine

Technical field

The invention belongs to medical product research and development field, be specifically related to the application of EPA in preparation protection Potassium bromate. induction body oxidative stress injury of kidney medicine.

Background technology

Research in recent years shows, Potassium bromate. can bring out people and other mammiferous Renal tissues damages.According to the literature, the injury of kidney pathological process that Potassium bromate. causes is from kidney response to oxidative stress, and kidney stress produce and accumulating a large amount of oxygen-derived free radicals and lipid peroxidation occurs under load condition, and then affects cell membrane function, cause nephropathy ( watanabe, Satoshi; Yoshimura, Yoshihiro; Fukui, Tetsuya. Contribution of glutathione peroxidase and nitric oxide to potassium bromate-induced oxidative stress and kidney damage in mice[J]. Journal of Health Science, 2001,47 (6): 565-570.).

Eicosapentaenoic acid (EPA) is one of necessary polybasic unsaturated fatty acid of human body, belongs to the serial polyunsaturated fatty acid in ω-3, is common in the bathypelagic fish oil such as salmon, mackerel, sardine.< < modern food science and technology > > discloses the pharmaceutical usage of EPA for 2006 in the 22nd the 3rd phase of volume " trophic function of EPA, a DHA and Product Safety analysis " literary composition; comprise prevention to cardiovascular disease, to the growth of cancerous cell and metastasis inhibition, antiinflammatory antiallergic, brain-strengthening item effect etc., but the not mentioned protective effect to Potassium bromate. induced oxidation irritability injury of kidney.

Summary of the invention

The object of the present invention is to provide the new purposes of a kind of EPA, the defect existing to solve existing protection Potassium bromate. induction body oxidative stress injury of kidney medicine.

To achieve the above object of the invention, the technical solution used in the present invention is: the application of a kind of EPA in preparation protection oxidative stress injury of kidney medicine.

Above-mentioned oxidative stress injury of kidney disease is Potassium bromate. induction body oxidative stress injury of kidney.

In said medicine, the purity of EPA is 66 ~ 99.9%.

Consumption >=1mL of EPA in said medicine.

EPA of the present invention can be individually dosed or be made preparation administration with acceptable carrier combination agent, and various dosage forms can be according to the method preparation of knowing in pharmaceutical field.Described EPA is suitable for oral administration, intravenously administrable, subcutaneous administration, intramuscular administration.

The invention provides a kind of new purposes of EPA, the EPA of take probes into it in the effect of performance aspect Potassium bromate. induction body oxidative stress injury of kidney as raw material.Pharmacological evaluation demonstration, EPA can make the serum creatinine level of pathological state lower body significantly reduce, thereby can be used for the medicine of preparation protection Potassium bromate. induction body oxidative stress injury of kidney.This research is induced body oxidative stress injury of kidney medicine for Future Development preparation protection Potassium bromate. and has been established important foundation.

Accompanying drawing explanation

Fig. 1 is the purity of EPA while being 66%, the impact of EPA on Potassium bromate. induction body oxidative stress injury of kidney mice serum creatinine level;

Fig. 2 is the purity of EPA while being 81%, the impact of EPA on Potassium bromate. induction body oxidative stress injury of kidney mice serum creatinine level;

Fig. 3 is the purity of EPA while being 99%, the impact of EPA on Potassium bromate. induction body oxidative stress injury of kidney mice serum creatinine level;

In figure, ## represents to compare with normal group, p<0.01; * represent to compare with model group p<0.05.

The specific embodiment

Below in conjunction with drawings and Examples, the invention will be further described.

Embodiment

The protective effect of EPA to Potassium bromate. inducing mouse oxidative stress injury of kidney.

Material and reagent: EPA (purity: 66%, 81%, 99%, self-control); Creatinine (chemical reference substance, content 99.8% Nat'l Pharmaceutical & Biological Products Control Institute); Potassium dihydrogen phosphate (analytical pure, Chemical Reagent Co., Ltd., Sinopharm Group), potassium hydroxide (analytical pure, Chemical Reagent Co., Ltd., Sinopharm Group); Potassium bromate. (analytical pure, Shanghai Lin Di Chemical Co., Ltd.).

Laboratory animal: Kunming clean level mice, male, body weight 18-22g, purchased from Shanghai Slac Experimental Animal Co., Ltd., credit number SCXK(Shanghai) 2012-0002.23 ± 1 ℃ of raising temperatures, lighting hours 12h/d(7:00-19:00).

1 animals administer

80 adaptabilities of mice were fed after one week, after weighing, by body weight, were evenly divided into normal group, model group, EPA low dose group 1, EPA high dose group 1, EPA low dose group 2, EPA high dose group 2, EPA low dose group 3, EPA high dose group 3,10 every group.It is as follows that each organizes medication.

(1) normal group

1-7 days, gives normal food and water every day; The 7th day, gavage distilled water, 10mL/Kg mice; After 0.5 hour, intraperitoneal injection of saline, 10mL/Kg mice; Within 9 hours, laggard row serum creatinine level is measured.

(2) model group

1-7 days, gives normal food and water every day; The 7th day, gavage distilled water, 10mL/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline solution, 10mL/Kg mice, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.

(3) EPA low dose group 1

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 1 mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 66% herein.

(4) EPA high dose group 1

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 5mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 66% herein.

(5) EPA low dose group 2

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 1 mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 81% herein.

(6) EPA high dose group 2

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 5mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 81% herein.

(7) EPA low dose group 3

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 1 mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 99% herein.

(8) EPA high dose group 3

1-7 days, gives normal food and water every day; The 7th day, gavage was given EPA, 5mL EPA/Kg mice; After 0.5 hour, lumbar injection is given Potassium bromate. normal saline, 200 mg Potassium bromate ./Kg mices; Within 9 hours, laggard row serum creatinine level is measured.Note: EPA purity is 99% herein.

2 serum creatinine level are measured

Eyeball of mouse is got after blood, standing 30 min, at 4 ℃ with centrifugal 10 min of speed of 5000 rpm; Separation of serum, adds isopyknic 6% perchloric acid Deproteinization, the centrifugal 15min of 12000 rpm; Get supernatant, with 0.45 μ m filtering with microporous membrane, and preserve at-20 ℃, for creatinine level, measure.Measure and use the Japanese Nacalai Tesque Cosmosil of company series 5 C18 posts (4.6 mm * 150 mm), mobile phase: 20 mmol/L phosphate buffered solution (PH=6.5), flow velocity 1 mL/min, column temperature is 25 ℃, detects wavelength 235 nm.Creatinine standard substance dissolve by mobile phase and are diluted to variable concentrations, for production standard curve.

3 statistical analysis

Experimental result represents with average ± standard error (mean ± S.E.M), adopt SPSS 13.0 softwares, utilize single factor analysis (one-way ANOVA) and Dunnett check to carry out statistical procedures, p<0.05 indicates significant difference, has statistical significance.

The serum creatinine level impact of EPA on Potassium bromate. induction body oxidative stress injury of kidney mice, experimental result is as follows:

(1), from accompanying drawing 1, when EPA active component content is 60%, model group is compared creatinine content significantly raise (p<0.01) with normal group; Gavage gives after EPA, and EPA high dose group is compared creatinine content and significantly reduced (p<0.05) with model group.

(2), from accompanying drawing 2, when EPA active component content is 80%, model group is compared creatinine content significantly raise (p<0.01) with normal group; Gavage gives after EPA, EPA low dose group is compared creatinine content and is significantly reduced (p<0.05) with model group, EPA high dose group is compared creatinine content and is significantly reduced (p<0.05) with model group, and the effect of high dose is better than low dosage.

(3), from accompanying drawing 3, when EPA active component content is 80%, model group is compared creatinine content significantly raise (p<0.01) with normal group; Gavage gives after EPA, EPA low dose group is compared creatinine content and is significantly reduced (p<0.05) with model group, EPA high dose group is compared creatinine content and is significantly reduced (p<0.05) with model group, and the effect of high dose is better than low dosage.

From above embodiment result, EPA has significant protective effect to Potassium bromate. induction body oxidative stress injury of kidney, and EPA can be used for the preparation of Potassium bromate. induction body oxidative stress injury of kidney medicine.

Claims

1. an EPA protects the application in oxidative stress injury of kidney medicine in preparation.

2. application according to claim 1, is characterized in that: described oxidative stress injury of kidney disease is Potassium bromate. induction body oxidative stress injury of kidney.

3. application according to claim 1, is characterized in that: described EPA purity is 66 ~ 99.9%.

4. application according to claim 1, is characterized in that: consumption >=1mL of described EPA.